Prescription required. We facilitate access to medicines already prescribed by your treating physician. We do not provide medical advice or diagnoses.
Ibrutinib Side Effects: What to Expect and When to Call Your Doctor
IBRUTINIB PATIENT EDUCATION | Last reviewed: June 2026 | Medical reviewer: [Salma Mamdouh Elreedy]
Ibrutinib (brand name: Imbruvica) is an oral targeted therapy used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinemia. It works by blocking a protein called Bruton’s tyrosine kinase (BTK), which cancer cells need to grow and survive.
Most side effects are mild and improve within the first few weeks of treatment. A small number are serious and need prompt medical attention. This article explains both — in plain language.
| ⚠️ When to call your doctor right away: Fever above 100.4°F (38°C) — irregular or rapid heartbeat — unusual or heavy bleeding — shortness of breath — yellowing of skin or eyes. These may signal a serious complication that requires same-day evaluation. |
Common Side Effects (Occur in More Than 20% of Patients)
These are the side effects most patients report. They are usually manageable and often lessen after the first few months of treatment.
| Side Effect | Reported Frequency | Tier |
| Diarrhea | Most common (≥20%) | Common — usually manageable |
| Fatigue | ≥20% of patients | Common — usually manageable |
| Musculoskeletal pain (muscle, bone, joint) | ≥20% of patients | Common — usually manageable |
| Bruising / easy contusion | Up to 51% | Common — usually manageable |
| Rash | Up to 49% | Common — usually manageable |
| Nausea | ≥20% of patients | Common — usually manageable |
| Neutropenia (low white blood cells) | ≥20% of patients | Serious — seek care promptly |
| Upper respiratory tract infection | ≥20% of patients | Common — usually manageable |
Source: FDA Prescribing Information for ibrutinib (Imbruvica); Drugs.com ibrutinib side effects summary (updated May 2026).
Diarrhea
Diarrhea is one of the most frequently reported side effects. Drink plenty of fluids to prevent dehydration. Avoid spicy, greasy, or high-fiber foods during flare-ups. Eat small, frequent meals. Tell your doctor if diarrhea persists for more than two days or is severe.
Fatigue
Many patients feel tired, especially in the first weeks of treatment. Light activity, such as short walks, can help. Balance movement with rest. If fatigue is severe enough to interfere with daily life, speak with your care team — it may be related to anemia, which is treatable.
Bruising and Bleeding
Ibrutinib affects platelet signaling, which makes bruising more likely. Minor bruising is common and not usually a cause for alarm. However, unusual bleeding — such as prolonged bleeding after a cut, blood in your urine or stool, or unexplained heavy bruising — needs prompt attention.
Rash
Skin rashes, particularly early in treatment, are common. Most are mild. Use gentle, fragrance-free skincare products. Avoid prolonged sun exposure and wear sunscreen. Petechiae (tiny red or purple dots on the skin) are also reported and should be mentioned to your doctor.
Serious Side Effects That Require Prompt Medical Attention
These side effects are less common but can be life-threatening if not addressed quickly. Your care team will monitor you for these throughout treatment.
1. Atrial Fibrillation (Irregular Heartbeat)
Atrial fibrillation (AF) is the most significant cardiac side effect of ibrutinib. In clinical trials, AF occurs in approximately 6–16% of patients. Real-world studies of CLL patients have found rates as high as 18%. The risk increases with longer treatment duration: in the first 18 months, rates are 3–7%; after 60 months, they rise to 9–16%.
Pre-existing heart disease increases your AF risk further. A 2025 network meta-analysis confirmed that ibrutinib carries a significantly higher AF risk than chemoimmunotherapy (OR 4.95).
| ❤️ Heart symptoms to report immediately: Racing or irregular heartbeat — lightheadedness or dizziness — chest discomfort — shortness of breath — swelling in the legs or ankles. |
2. High Blood Pressure (Hypertension)
Hypertension has been reported in up to 42% of patients receiving ibrutinib long-term. About 8% experience Grade 3 hypertension (significantly elevated blood pressure). Monitor your blood pressure regularly at home. Your doctor may start or adjust blood pressure medication at any point during treatment.
3. Serious Bleeding
Major bleeding events occur in 1–8% of patients. The risk is higher if you also take blood thinners or anti-platelet medications such as aspirin. Avoid combining these with ibrutinib unless your oncologist has reviewed the risks. Tell your surgeon or dentist that you take ibrutinib before any procedure, and follow your doctor’s instructions about stopping the drug before surgery.
4. Serious Infections
Ibrutinib suppresses the immune system. Grade 3 or higher infections (pneumonia, sepsis, and others) occur in approximately 21% of patients treated in clinical trials. Pneumonia is one of the most common serious infections. Call your doctor immediately if you develop fever, chills, or any signs of infection. Do not take herbal supplements or over-the-counter medicines that affect immunity without checking first.
5. Tumor Lysis Syndrome (TLS)
TLS happens when cancer cells break down rapidly, releasing substances into the bloodstream that can overwhelm the kidneys. It is most likely when starting treatment. Symptoms include muscle cramps, nausea, fatigue, decreased urination, or irregular heartbeat. Your care team will often run blood tests to detect TLS early.
6. Second Primary Cancers
New cancers have been reported in patients taking ibrutinib, including skin cancers (melanoma in ~6% and non-skin cancers in ~4%). Protect your skin from sun exposure. Have regular skin checks. Report any new or unusual skin changes to your doctor.
Long-Term Side Effects of Ibrutinib
Research shows that certain side effects do not plateau — they continue to increase over time. Atrial fibrillation and high blood pressure are the two most important examples. A 2024 update from the A041202 long-term follow-up study concluded that these cardiovascular risks continue to accumulate and are the primary reason newer BTK inhibitors (such as acalabrutinib and zanubrutinib) are now more widely used in the US for certain patients.
Other long-term effects that have been observed include:
- Hair changes: Textural changes (softening, straightening, or increased curliness). Hair loss is not listed in the product label, but nail changes (brittle nails) have been noted.
- Joint and muscle pain that may persist or worsen.
- Fatigue that continues beyond the first months in some patients.
- Increased susceptibility to infection due to ongoing immune suppression.
Source: Woyach JA et al. Blood (2024). Long-term follow-up from A041202 showing continued efficacy and cardiovascular risks of ibrutinib in older CLL patients.
Managing Side Effects: Practical Tips
Many side effects can be minimized with simple day-to-day habits. Discuss these with your care team and do not make dose changes on your own.
For Diarrhea and Nausea
- Drink water, clear broths, and decaffeinated tea throughout the day.
- Eat five or six small meals rather than three large ones.
- Avoid spicy food, greasy food, bran, and raw fruits or vegetables during flare-ups.
- Ask your doctor about over-the-counter options such as loperamide.
For Bruising and Skin
- Avoid aspirin and NSAIDs (ibuprofen, naproxen) unless your oncologist approves.
- Use fragrance-free, gentle soaps and moisturizers.
- Wear sunscreen (SPF 30 or higher) daily.
- Wear protective clothing in sunlight to reduce skin cancer risk.
For Fatigue
- Take short walks and stay lightly active if you feel well enough.
- Rest when needed — but avoid staying in bed all day, as this can worsen fatigue.
- Tell your doctor if fatigue is severe. A blood count check can rule out anemia.
For Heart Health
- Monitor your blood pressure at home with a personal cuff. Log readings and share them with your care team.
- Limit alcohol and caffeine intake.
- Avoid grapefruit and Seville oranges: these can increase ibrutinib levels in your blood.
- Tell your cardiologist (if you have one) that you are taking ibrutinib.
| 💊 Dose adjustments are available: Your doctor may reduce your dose from 420 mg to 280 mg or 140 mg daily, or pause treatment temporarily, to manage side effects. Do not adjust your dose on your own. Always talk to your care team first. |
Side Effects in Special Populations
Patients with Pre-Existing Heart Disease
If you have a history of atrial fibrillation, hypertension, or other heart conditions, your risk of cardiovascular side effects on ibrutinib is higher. Your care team may recommend closer monitoring, a cardiology consultation, or discussion of whether a newer BTK inhibitor may be more appropriate.
Older Adults
Real-world data show that patients over 65 have higher rates of atrial fibrillation (14.8% in one large cohort) and major bleeding compared to younger patients. Older adults may also have more difficulty tolerating prolonged fatigue or infection. If you are older and finding side effects difficult, discuss whether dose reduction or treatment modification makes sense for you.
Patients on Blood Thinners
Combining ibrutinib with anticoagulants such as warfarin or direct oral anticoagulants (DOACs) significantly raises bleeding risk. The same applies to antiplatelet drugs such as aspirin or clopidogrel. Your oncologist and primary care doctor should coordinate carefully if you need these medications for another condition.
Frequently Asked Questions
Will side effects go away over time?
Many early side effects — including diarrhea, nausea, and fatigue — improve in the first few weeks to months. However, cardiovascular risks such as atrial fibrillation and hypertension tend to increase over time rather than resolve. Ongoing monitoring is important for as long as you take ibrutinib.
Is ibrutinib chemotherapy?
No. Ibrutinib is a targeted therapy (a BTK inhibitor), not traditional chemotherapy. It works differently from chemotherapy drugs, which typically kill rapidly dividing cells. Because ibrutinib targets a specific protein in cancer cells, it has a different side effect profile. Hair loss, for example, is not a listed side effect of ibrutinib, whereas it is common with many chemotherapy regimens.
Can I take over-the-counter medicines while on ibrutinib?
Some common medications interact with ibrutinib. Avoid NSAIDs and aspirin (unless specifically approved by your oncologist). Certain antifungal drugs, antibiotics, and supplements can also increase or decrease ibrutinib levels in your blood. Always check with your care team before adding any new medicine, supplement, or herbal product.
What if I miss a dose?
Take the missed dose on the same day as soon as you remember. Do not take two doses in one day. Contact your pharmacist or care team if you are unsure.
References
The following sources informed the clinical information in this article.
- FDA Prescribing Information, ibrutinib (Imbruvica). AbbVie Inc. / Pharmacyclics LLC. Available at: imbruvica.com.
- Drugs.com. Ibrutinib side effects — consumer and professional information. Updated May 2026.
- Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019. PMID: 30878129.
- Woyach JA, Perez Burbano GE, Ruppert AS, et al. Long-term follow-up from A041202. Blood. 2024. doi:10.1182/blood.2023021959.
- Incidence of atrial fibrillation and bleeding complications linked to ibrutinib treatment: A systematic review and network meta-analysis. ScienceDirect / Blood Cancer. 2025.
- Ibrutinib-associated cardiotoxicity: from the pharmaceutical to the clinical. Drug Des Devel Ther / PMC. 2022. PMC9508996.
- Bayesian network meta-analysis of cardiac safety of BTK inhibitors. Circulation. 2025.
Medical Disclaimer: This article is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your oncologist or pharmacist with any questions you may have about your medication. Never disregard professional medical advice or delay seeking it because of something you have read here.
